Table of Content

1. Executive Summary


2. Introduction

2.1 HIV Treatment: An Overview
2.1.1 Definition of HIV Treatment
2.1.2 Goals of HIV Treatment
2.1.3 HIV Treatment By Medication Class

2.2 HIV Treatment Segmentation: An Overview
2.2.1 HIV Treatment Segmentation By Product


3. Global Market Analysis

3.1 Global HIV Treatment Market: An Analysis

3.1.1 Global HIV Treatment Market: An Overview
3.1.2 Global HIV Treatment Market by Value
3.1.3 Global HIV Treatment Market by Product (Biktarvy, Genvoya, Triumeq, Dovato, Tivicay, Odefsey, Juluca, Descovy, Cabenuva, Truvada, Atripla, and Generics)
3.1.4 Global HIV Treatment Market by Region (the US, and European Union + Rest of World)

3.2 Global HIV Treatment Market: Product Analysis

3.2.1 Global HIV Treatment Market by Product: An Overview
3.2.2 Global Biktarvy HIV Treatment Market by Value
3.2.3 Global Genvoya HIV Treatment Market by Value
3.2.4 Global Triumeq HIV Treatment Market by Value
3.2.5 Global Dovato HIV Treatment Market by Value
3.2.6 Global Tivicay HIV Treatment Market by Value
3.2.7 Global Odefsey HIV Treatment Market by Value
3.2.8 Global Juluca HIV Treatment Market by Value
3.2.9 Global Descovy HIV Treatment Market by Value
3.2.10 Global Cabenuva HIV Treatment Market by Value
3.2.11 Global Truvada HIV Treatment Market by Value
3.2.12 Global Atripla HIV Treatment Market by Value
3.2.13 Global Sunlenca (Lenacapavir) HIV Treatment Market by Value
3.2.14 Global VH184 HIV Treatment Market by Value
3.2.15 Global Capsid HIV Treatment Market by Value
3.2.16 Global bNAbs HIV Treatment Market by Value
3.2.17 Global Islatravir HIV Treatment Market by Value
3.2.18 Global Generics HIV Treatment Market by Value


4. Regional Market Analysis

4.1 The US HIV Treatment Market: An Analysis

4.1.1 The US HIV Treatment Market: An Overview
4.1.2 The US HIV Treatment Market by Value
4.1.3 The US HIV Treatment Market by Product (Biktarvy, Genvoya, Triumeq, Odefsey, Tivicay, Dovato, Juluca, Descovy, Cabenuva, Truvada, Atripla, and Generics)

4.2 The US HIV Treatment Market: Product Analysis

4.2.1 The US HIV Treatment Market by Product: An Overview
4.2.2 The US Biktarvy HIV Treatment Market by Value
4.2.3 The US Genvoya HIV Treatment Market by Value
4.2.4 The US Triumeq HIV Treatment Market by Value
4.2.5 The US Dovato HIV Treatment Market by Value
4.2.6 The US Tivicay HIV Treatment Market by Value
4.2.7 The US Odefsey HIV Treatment Market by Value
4.2.8 The US Juluca HIV Treatment Market by Value
4.2.9 The US Descovy HIV Treatment Market by Value
4.2.10 The US Cabenuva HIV Treatment Market by Value
4.2.11 The US Truvada HIV Treatment Market by Value
4.2.12 The US Atripla HIV Treatment Market by Value
4.2.13 The US Sunlenca (Lenacapavir) HIV Treatment Market by Value
4.2.14 The US VH184 HIV Treatment Market by Value
4.2.15 The US Capsid HIV Treatment Market by Value
4.2.16 The US bNAbs HIV Treatment Market by Value
4.2.17 The US Islatravir HIV Treatment Market by Value
4.2.18 The US Generics HIV Treatment Market by Value

4.3 European Union + Rest of World HIV Treatment Market: An Analysis

4.3.1 European Union + Rest of World HIV Treatment Market: An Overview
4.3.2 European Union + Rest of World HIV Treatment Market by Value
4.3.3 European Union + Rest of World HIV Treatment Market by Product (Biktarvy, Dovato, Triumeq, Tivicay, Genvoya, Odefsey, Juluca, Descovy, Cabenuva, Truvada, and Atripla)

4.4 European Union + Rest of World HIV Treatment Market: Product Analysis

4.4.1 European Union + Rest of World HIV Treatment Market by Product: An Overview
4.4.2 European Union + Rest of World Biktarvy HIV Treatment Market by Value
4.4.3 European Union + Rest of World Genvoya HIV Treatment Market by Value
4.4.4 European Union + Rest of World Triumeq HIV Treatment Market by Value
4.4.5 European Union + Rest of World Dovato HIV Treatment Market by Value
4.4.6 European Union + Rest of World Tivicay HIV Treatment Market by Value
4.4.7 European Union + Rest of World Odefsey HIV Treatment Market by Value
4.4.8 European Union + Rest of World Juluca HIV Treatment Market by Value
4.4.9 European Union + Rest of World Descovy HIV Treatment Market by Value
4.4.10 European Union + Rest of World Cabenuva HIV Treatment Market by Value
4.4.11 European Union + Rest of World Truvada HIV Treatment Market by Value
4.4.12 European Union + Rest of World Atripla HIV Treatment Market by Value
4.4.13 European Union + Rest of World Sunlenca (Lenacapavir) HIV Treatment Market by Value
4.4.14 European Union + Rest of World VH184 HIV Treatment Market by Value
4.4.15 European Union + Rest of World Capsid HIV Treatment Market by Value
4.4.16 European Union + Rest of World bNAbs HIV Treatment Market by Value
4.4.17 European Union + Rest of World Islatravir HIV Treatment Market by Value


5. Impact of COVID-19

5.1 Impact of COVID-19 on Global HIV Treatment Market
5.2 Post-COVID-19 Impact on Global HIV Treatment Market


6. Market Dynamics

6.1 Growth Driver
6.1.1 Rising HIV Prevalence
6.1.2 Advancements in Antiretroviral Therapy (ART)
6.1.3 Rising Disposable Income
6.1.4 Increased Government Funding and Initiatives
6.1.5 Expansion of Generic Drugs
6.1.6 Growing Awareness and Testing
6.1.7 Public-private Partnerships

6.2 Challenges
6.2.1 Drug Resistance
6.2.2 Stigma, Discrimination, and Access to Treatment
6.2.3 Loss of Patent Protection

6.3 Market Trends
6.3.1 Increasing Penetration of Artificial Intelligence
6.3.2 Increasing Adoption of Telemedicine
6.3.3 Development of Long-acting Injectable
6.3.4 Advances in Gene Therapy
6.3.5 Focus on Combination Therapies


7. Competitive Landscape

7.1 Global HIV Treatment Market: Competitive Landscape
7.2 Global HIV Treatment Market Players: Approved Product List


8. Company Profiles

8.1 Gilead Sciences, Inc.
8.1.1 Business Overview
8.1.2 Sales by Product
8.1.3 Business Strategy

8.2 GlaxoSmithKline Plc (ViiV Healthcare)
8.2.1 Business Overview
8.2.2 Sales by Products
8.2.3 Business Strategy

8.3 Merck & Co., Inc.
8.3.1 Business Overview
8.3.2 Operating Segments
8.3.3 Business Strategy

8.4 Abbott Laboratories
8.4.1 Business Overview
8.4.2 Revenue by Category
8.4.3 Business Strategy

8.5 AbbVie Inc.
8.5.1 Business Overview
8.5.2 Operating Regions
8.5.3 Business Strategy

8.6 TEVA Pharmaceutical Industries Limited
8.6.1 Business Overview
8.6.2 Operating Segments
8.6.3 Business Strategy

8.7 Johnson & Johnson (Janssen Pharmaceuticals)
8.7.1 Business Overview
8.7.2 Business Segments
8.7.3 Business Strategy

8.8 Boehringer Ingelheim
8.8.1 Business Overview
8.8.2 Operating Business
8.8.3 Business Strategy

8.9 Cipla Limited
8.9.1 Business Overview
8.9.2 Operating Segments
8.9.3 Business Strategy

8.10 Viatris Inc.
8.10.1 Business Overview
8.10.2 Operating Segments
8.10.3 Business Strategy

8.11 Bristol-Myers Squibb Company
8.11.1 Business Overview
8.11.2 Revenue by Product
8.11.3 Business Strategy

8.12 Hetero Drugs Limited
8.12.1 Business Overview
8.12.2 Business Strategy

List of Figures

Figure 1: Goals of HIV Treatment
Figure 2: HIV Treatment by Medication Class
Figure 3: HIV Treatment Segmentation by Product
Figure 4: Global HIV Treatment Market by Value; 2020-2022 (US$ Billion)
Figure 5: Global HIV Treatment Market by Value; 2023-2030 (US$ Billion)
Figure 6: Global HIV Treatment Market by Product; 2022 (Percentage, %)
Figure 7: Global HIV Treatment Market by Region; 2022 (Percentage, %)
Figure 8: Global Biktarvy HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Figure 9: Global Biktarvy HIV Treatment Market by Value, 2023-2030 (US$ Billion)
Figure 10: Global Genvoya HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Figure 11: Global Genvoya HIV Treatment Market by Value, 2023-2030 (US$ Billion)
Figure 12: Global Triumeq HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Figure 13: Global Triumeq HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 14: Global Dovato HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Figure 15: Global Dovato HIV Treatment Market by Value, 2023-2030 (US$ Billion)
Figure 16: Global Tivicay HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Figure 17: Global Tivicay HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 18: Global Odefsey HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Figure 19: Global Odefsey HIV Treatment Market by Value, 2023-2030 (US$ Billion)
Figure 20: Global Juluca HIV Treatment Market by Value, 2020-2022 (US$ Million)
Figure 21: Global Juluca HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 22: Global Descovy HIV Treatment Market by Value, 2020-2022 (US$ Million)
Figure 23: Global Descovy HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 24: Global Cabenuva HIV Treatment Market by Value, 2020-2022 (US$ Million)
Figure 25: Global Cabenuva HIV Treatment Market by Value, 2023-2030 (US$ Billion)
Figure 26: Global Truvada HIV Treatment Market by Value, 2020-2022 (US$ Million)
Figure 27: Global Truvada HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 28: Global Atripla HIV Treatment Market by Value, 2020-2022 (US$ Million)
Figure 29: Global Atripla HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 30: Global Sunlenca (Lenacapavir) HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 31: Global VH184 HIV Treatment Market by Value; 2030 (US$ Million)
Figure 32: Global Capsid HIV Treatment Market by Value; 2027-2030 (US$ Million)
Figure 33: Global bNAbs HIV Treatment Market by Value, 2027-2030 (US$ Million)
Figure 34: Global Islatravir HIV Treatment Market by Value; 2024-2030 (US$ Billion)
Figure 35: Global Generics HIV Treatment Market by Value, 2020-2022 (US$ Million)
Figure 36: Global Generics HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 37: The US HIV Treatment Market by Value; 2020-2022 (US$ Billion)
Figure 38: The US HIV Treatment Market by Value; 2023-2030 (US$ Billion)
Figure 39: The US HIV Treatment Market by Product; 2022 (Percentage, %)
Figure 40: The US Biktarvy HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Figure 41: The US Biktarvy HIV Treatment Market by Value, 2023-2030 (US$ Billion)
Figure 42: The US Genvoya HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Figure 43: The US Genvoya HIV Treatment Market by Value, 2023-2030 (US$ Billion)
Figure 44: The US Triumeq HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Figure 45: The US Triumeq HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 46: The US Dovato HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Figure 47: The US Dovato HIV Treatment Market by Value, 2023-2030 (US$ Billion)
Figure 48: The US Tivicay HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Figure 49: The US Tivicay HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 50: The US Odefsey HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Figure 51: The US Odefsey HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 52: The US Juluca HIV Treatment Market by Value, 2020-2022 (US$ Million)
Figure 53: The US Juluca HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 54: The US Descovy HIV Treatment Market by Value, 2020-2022 (US$ Million)
Figure 55: The US Descovy HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 56: The US Cabenuva HIV Treatment Market by Value, 2020-2022 (US$ Million)
Figure 57: The US Cabenuva HIV Treatment Market by Value, 2023-2030 (US$ Billion)
Figure 58: The US Truvada HIV Treatment Market by Value, 2020-2022 (US$ Million)
Figure 59: The US Truvada HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 60: The US Atripla HIV Treatment Market by Value, 2020-2022 (US$ Million)
Figure 61: The US Atripla HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 62: The US Sunlenca (Lenacapavir) HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 63: The US VH184 HIV Treatment Market by Value, 2030 (US$ Million)
Figure 64: The US Capsid HIV Treatment Market by Value, 2027-2030 (US$ Million)
Figure 65: The US bNAbs HIV Treatment Market by Value, 2027-2030 (US$ Million)
Figure 66: The US Islatravir HIV Treatment Market by Value, 2024-2030 (US$ Million)
Figure 67: The US Generics HIV Treatment Market by Value, 2020-2022 (US$ Million)
Figure 68: The US Generics HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 69: European Union + Rest of World HIV Treatment Market by Value; 2020-2022 (US$ Billion)
Figure 70: European Union + Rest of World HIV Treatment Market by Value; 2023-2030 (US$ Billion)
Figure 71: European Union + Rest of World HIV Treatment Market by Product; 2022 (Percentage, %)
Figure 72: European Union + Rest of World Biktarvy HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Figure 73: European Union + Rest of World Biktarvy HIV Treatment Market by Value, 2023-2030 (US$ Billion)
Figure 74: European Union + Rest of World Genvoya HIV Treatment Market by Value, 2020-2022 (US$ Million)
Figure 75: European Union + Rest of World Genvoya HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 76: European Union + Rest of World Triumeq HIV Treatment Market by Value, 2020-2022 (US$ Billion)
Figure 77: European Union + Rest of World Triumeq HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 78: European Union + Rest of World Dovato HIV Treatment Market by Value, 2020-2022 (US$ Million)
Figure 79: European Union + Rest of World Dovato HIV Treatment Market by Value, 2023-2030 (US$ Billion)
Figure 80: European Union + Rest of World Tivicay HIV Treatment Market by Value, 2020-2022 (US$ Million)
Figure 81: European Union + Rest of World Tivicay HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 82: European Union + Rest of World Odefsey HIV Treatment Market by Value, 2020-2022 (US$ Million)
Figure 83: European Union + Rest of World Odefsey HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 84: European Union + Rest of World Juluca HIV Treatment Market by Value, 2020-2022 (US$ Million)
Figure 85: European Union + Rest of World Juluca HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 86: European Union + Rest of World Descovy HIV Treatment Market by Value, 2020-2022 (US$ Million)
Figure 87: European Union + Rest of World Descovy HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 88: European Union + Rest of World Cabenuva HIV Treatment Market by Value, 2020-2022 (US$ Million)
Figure 89: European Union + Rest of World Cabenuva HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 90: European Union + Rest of World Truvada HIV Treatment Market by Value, 2020-2022 (US$ Million)
Figure 91: European Union + Rest of World Truvada HIV Treatment Market by Value, 2023-2025 (US$ Million)
Figure 92: European Union + Rest of World Atripla HIV Treatment Market by Value, 2020-2022 (US$ Million)
Figure 93: European Union + Rest of World Atripla HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 94: European Union + Rest of World Sunlenca (Lenacapavir) HIV Treatment Market by Value, 2023-2030 (US$ Million)
Figure 95: European Union + Rest of World VH184 HIV Treatment Market by Value, 2030 (US$ Million)
Figure 96: European Union + Rest of World Capsid HIV Treatment Market by Value, 2027-2030 (US$ Million)
Figure 97: European Union + Rest of World bNAbs HIV Treatment Market by Value, 2027-2030 (US$ Million)
Figure 98: European Union + Rest of World Islatravir HIV Treatment Market by Value, 2024-2030 (US$ Million)
Figure 99: Global Number of HIV Patients (Living with & Newly Infected); 2021 (Million)
Figure 100: The US, and EU Number of HIV Patients (Prevalent, Diagnosed & Treated); 2021 (Million)
Figure 101: Global Coverage of Antiretroviral Treatment (ART); 2021 (Percentage, %)
Figure 102: Global Coverage of Antiretroviral Treatment (ART) Among Children & Prevention Of Mother-to-child Transmission (PMTCT); 2015- 2021 (Percentage, %)
Figure 103: Advanced Economies and Emerging Market & Developing Economies GDP Per Capita; 2018-2027 (US$ Thousand)
Figure 104: HIV Funding from Donor Governments; 2015-2021 (US$ Billion)
Figure 105: The US Federal Domestic Discretionary Funding for HIV/AIDS; 2021-2024 (US$ Million)
Figure 106: Global Artificial Intelligence (AI) Market Revenues; 2020-2023 (US$ Billion)
Table 2: Global HIV Treatment Market Players: Approved Product List; 2022
Figure 107: Gilead Sciences, Inc. Sales by Product; 2022 (Percentage, %)
Figure 108: GlaxoSmithKline Plc Sales by Products; 2022 (Percentage, %)
Figure 109: Merck & Co., Inc. Sales by Segments; 2022 (Percentage, %)
Figure 110: Abbott Laboratories Revenue by Category; 2022 (Percentage, %)
Figure 111: AbbVie Inc. Net revenue by Regions; 2022 (Percentage, %)
Figure 112: TEVA Pharmaceutical Industries Ltd., Revenues by Segment; 2021 (Percentage, %)
Figure 113: Johnson & Johnson Sales by Business Segment; 2022 (Percentage, %)
Figure 114: Boehringer Ingelheim Net Sales by Business; 2022 (Percentage, %)
Figure 115: Cipla Limited Revenue by Segment; 2022 (Percentage, %)
Figure 116: Viatris Inc. Net Sales by Segment; 2022 (Percentage, %)
Figure 117: Bristol-Myers Squibb Company Revenue by Product; 2022 (Percentage, %)
Table 1: FDA-Approved Generic Drugs For HIV Treatment; Until 2022